Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$82.17 USD

82.17
7,884,447

-9.03 (-9.90%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $82.02 -0.15 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for BioMarin Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,074 1,292 1,014 1,065 754
Receivables 634 461 373 448 377
Notes Receivable 0 0 0 0 0
Inventories 1,107 894 777 699 680
Other Current Assets 141 105 110 130 131
Total Current Assets 2,956 2,751 2,274 2,342 1,942
Net Property & Equipment 1,066 1,073 1,035 1,032 1,011
Investments & Advances 611 334 508 285 412
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,546 1,505 1,449 1,432 549
Intangibles 491 535 585 613 654
Deposits & Other Assets 172 176 152 142 122
Total Assets 6,842 6,375 6,003 5,848 4,690
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 683 573 492 493 571
Current Portion Long-Term Debt 494 0 0 0 362
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 16 48 0 0
Total Current Liabilities 1,177 589 540 493 933
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 593 1,083 1,079 1,075 486
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 120 100 114 174 149
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,890 1,772 1,733 1,742 1,568
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 5,612 5,405 5,192 4,993 4,833
Retained Earnings -622 -789 -926 -862 -1,721
Other Equity -39 -13 5 -26 10
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 4,952 4,603 4,271 4,106 3,122
Total Liabilities & Shareholder's Equity 6,842 6,375 6,003 5,848 4,690
Total Common Equity 4,952 4,603 4,271 4,106 3,122
Shares Outstanding 188.30 185.40 183.50 181.50 179.60
Book Value Per Share 26.30 24.83 23.27 22.62 17.39

Fiscal Year End for BioMarin Pharmaceutical Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,074 1,126 1,171 1,152
Receivables NA 634 573 610 598
Notes Receivable NA 0 0 0 0
Inventories NA 1,107 1,032 976 919
Other Current Assets NA 141 225 193 173
Total Current Assets NA 2,956 2,955 2,950 2,842
Net Property & Equipment NA 1,066 1,067 1,067 1,068
Investments & Advances NA 611 548 386 341
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 1,546 1,524 1,509 1,511
Intangibles NA 491 499 507 522
Deposits & Other Assets NA 172 165 144 150
Total Assets NA 6,842 6,758 6,563 6,434
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 683 670 597 598
Current Portion Long-Term Debt NA 494 493 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 1,177 1,163 597 598
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 593 593 1,085 1,084
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 105 98 92
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,890 1,861 1,780 1,775
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 5,612 5,543 5,494 5,418
Retained Earnings NA -622 -642 -682 -738
Other Equity NA -39 -4 -29 -21
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 4,952 4,897 4,783 4,659
Total Liabilities & Shareholder's Equity NA 6,842 6,758 6,563 6,434
Total Common Equity 0 4,952 4,897 4,783 4,659
Shares Outstanding 188.60 188.30 188.30 188.10 187.70
Book Value Per Share 0.00 26.30 26.01 25.43 24.82